ADIL
NASDAQAdial Pharmaceuticals Inc
Adial Pharmaceuticals Inc (ADIL) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 12 wire items for ADIL, including 6 SEC filings, 3 insider trades and 2 leadership changes. The most recent was published Oct 31, 2026.
Financial highlights
Full financials- Net income, TTM
- -$57.80M
- Cash
- $28.71M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks44+71%
2026-05-102026-11-01
Mix3090d
- SEC Filings20(67%)
- Other4(13%)
- Insider4(13%)
- Leadership2(7%)
Latest news
25 items- INSIDERSEC Form 4 filed by Adial Pharmaceuticals Inc4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 3 filed by Adial Pharmaceuticals Inc3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 3 filed by Adial Pharmaceuticals Inc3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- SECSEC Form 8-K filed by Adial Pharmaceuticals Inc8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative ColitisStockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora’s common stock to begin trading on Nasdaq under the ticker symbol "AZR" New executive leadership team with deep experience spanning drug development and clinical expertise in AhR biology and inflammatory bowel disease Phase 1 clinical trial initiation of AT177 expected in the first half of 2027 LOS ANGELES, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s c
- SECSEC Form EFFECT filed by Adial Pharmaceuticals IncEFFECT - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial OfficerSeasoned public company CFO with deep autoimmune disease experience has helped raise more than $1 billion over a 20+ year biotech career Will lead the Company’s finance organization and capital strategy as it transitions to Azora Therapeutics and advances AT177 toward the clinic GLEN ALLEN, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Compa
- SECAmendment: SEC Form 10-Q/A filed by Adial Pharmaceuticals Inc10-Q/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAmendment: SEC Form S-3/A filed by Adial Pharmaceuticals IncS-3/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECSEC Form DEFA14A filed by Adial Pharmaceuticals IncDEFA14A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECSEC Form 8-K filed by Adial Pharmaceuticals Inc8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative ColitisFormer Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization Will lead AT177 through IND-enabling studies toward first-in-human trials expected in 2027 GLEN ALLEN, Va., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company's research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon recep
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Other Events8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company. The option award has an exercise price of $4.22 per share, the closing price of the Company’s common stock on September 25, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to
- INSIDERSEC Form 4 filed by Director Young Wendy B.4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- SECSEC Form DEFA14A filed by Adial Pharmaceuticals IncDEFA14A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECSEC Form DEFA14A filed by Adial Pharmaceuticals IncDEFA14A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECSEC Form S-3 filed by Adial Pharmaceuticals IncS-3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECSEC Form S-8 filed by Adial Pharmaceuticals IncS-8 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company. The option award has an exercise price of $5.76 per share, the closing price of the Company’s common stock on August 19, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the
- SECSEC Form DEF 14A filed by Adial Pharmaceuticals IncDEF 14A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
ADIL FAQ
10 questionsWhat does Adial Pharmaceuticals Inc do?
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.What is the latest news on ADIL?
In the last 30 days Quantisnow tracked 12 wire items for ADIL: 6 SEC filings, 3 insider trades, 2 leadership changes and 1 press release or news item. The most recent was published on October 31, 2026.Is ADIL profitable?
No. Adial Pharmaceuticals Inc reported a net loss of $57.80M for the twelve months ended Jun 30, 2026.How much cash and debt does ADIL have?
Adial Pharmaceuticals Inc reported $28.71M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ADIL stock trade?
Adial Pharmaceuticals Inc (ADIL) is listed on NASDAQ.What sector and industry is ADIL in?
Adial Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adial Pharmaceuticals Inc go public?
Adial Pharmaceuticals Inc (ADIL) completed its IPO in 2018.What are analysts saying about ADIL?
Adial Pharmaceuticals Inc has had 4 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $11.00 price target on 2026-08-03. Recent price targets range from $5.00 to $12.00.What companies are similar to ADIL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ADIL side-by-side with any of them on Quantisnow.How can I track ADIL on Quantisnow?
Quantisnow aggregates Adial Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADIL to receive live email and push alerts on every new disclosure.